AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
AngioDynamics (NASDAQ: ANGO) has announced it will release its fiscal 2025 second quarter financial results on January 8, 2025, before market open. The company will host two key events on the same day: a financial results conference call at 8:00 AM ET and a Virtual NanoKnife System investor event at 9:30 AM ET.
The conference call will be accessible via phone (1-877-407-0784 domestic, +1-201-689-8560 international) and webcast through the company's investor section website. A replay will be available until January 15, 2025, using passcode 13750571. The subsequent NanoKnife event aims to provide investors with deeper insights into the technology and company strategy.
AngioDynamics (NASDAQ: ANGO) ha annunciato che pubblicherà i risultati finanziari del secondo trimestre dell'esercizio 2025 il 8 gennaio 2025, prima dell'apertura del mercato. L'azienda ospiterà due eventi chiave lo stesso giorno: una conferenza telefonica sui risultati finanziari alle 8:00 AM ET e un evento per investitori sul sistema Virtual NanoKnife alle 9:30 AM ET.
La conferenza telefonica sarà accessibile tramite telefono (1-877-407-0784 nazionale, +1-201-689-8560 internazionale) e in webcast attraverso la sezione dedicata agli investitori del sito web dell'azienda. Una registrazione sarà disponibile fino al 15 gennaio 2025, utilizzando il codice di accesso 13750571. L'evento successivo sul NanoKnife ha l'obiettivo di fornire agli investitori approfondimenti più dettagliati sulla tecnologia e sulla strategia aziendale.
AngioDynamics (NASDAQ: ANGO) ha anunciado que publicará sus resultados financieros del segundo trimestre del año fiscal 2025 el 8 de enero de 2025, antes de la apertura del mercado. La compañía albergará dos eventos clave el mismo día: una conferencia telefónica sobre resultados financieros a las 8:00 AM ET y un evento para inversionistas del sistema Virtual NanoKnife a las 9:30 AM ET.
La conferencia telefónica será accesible por teléfono (1-877-407-0784 nacional, +1-201-689-8560 internacional) y a través de un webcast en la sección para inversionistas del sitio web de la empresa. Habrá una repetición disponible hasta el 15 de enero de 2025, usando el código de acceso 13750571. El evento posterior sobre NanoKnife tiene como objetivo proporcionar a los inversores una visión más profunda sobre la tecnología y la estrategia de la empresa.
AngioDynamics (NASDAQ: ANGO)는 2025 회계연도 2분기 재무 결과를 2025년 1월 8일 시장 개장 전에 발표할 것이라고 발표했습니다. 회사는 같은 날 두 가지 주요 이벤트를 개최합니다: 오전 8시(ET) 재무 결과에 대한 전화회의와 오전 9시 30분(ET) Virtual NanoKnife 시스템 투자자 이벤트입니다.
전화회의는 전화(1-877-407-0784 국내, +1-201-689-8560 국제)를 통해 액세스할 수 있으며, 회사의 투자자 섹션 웹사이트를 통해 웹캐스트로 진행됩니다. 2025년 1월 15일까지 사용할 수 있는 재생이 가능하며, 접근 코드 13750571을 사용해야 합니다. 그 후 NanoKnife 이벤트는 투자자들에게 기술 및 회사 전략에 대한 더 깊은 통찰력을 제공하는 것을 목표로 합니다.
AngioDynamics (NASDAQ: ANGO) a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre de l'exercice 2025 le 8 janvier 2025, avant l'ouverture du marché. L'entreprise organisera deux événements clés le même jour : une conférence téléphonique sur les résultats financiers à 8h00 ET et un événement pour investisseurs sur le système Virtual NanoKnife à 9h30 ET.
La conférence téléphonique sera accessible par téléphone (1-877-407-0784 national, +1-201-689-8560 international) et en webcast via la section investisseurs du site web de l'entreprise. Un enregistrement sera disponible jusqu'au 15 janvier 2025, en utilisant le code d'accès 13750571. L'événement NanoKnife qui suivra vise à fournir aux investisseurs des informations plus approfondies sur la technologie et la stratégie de l'entreprise.
AngioDynamics (NASDAQ: ANGO) hat angekündigt, dass die finanziellen Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 am 8. Januar 2025 vor der Markteröffnung veröffentlicht werden. Das Unternehmen wird am selben Tag zwei wichtige Veranstaltungen ausrichten: einen Konferenzanruf zu den Finanzergebnissen um 8:00 Uhr ET und ein Investorenevent zum Virtual NanoKnife-System um 9:30 Uhr ET.
Der Konferenzanruf ist per Telefon (1-877-407-0784 inländisch, +1-201-689-8560 international) sowie über einen Webcast über den Investorenbereich der Unternehmenswebsite zugänglich. Eine Wiederholung wird bis zum 15. Januar 2025 verfügbar sein, unter Verwendung des Zugangscodes 13750571. Die nachfolgende NanoKnife-Veranstaltung zielt darauf ab, Investoren tiefere Einblicke in die Technologie und die Unternehmensstrategie zu bieten.
- None.
- None.
Fiscal 2025 Second Quarter Financial Results Conference Call
The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international).
This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A recording of the call will also be available, until Wednesday, January 15, 2025 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13750571.
Virtual NanoKnife Investor Event
In an effort to provide investors more insight into the NanoKnife System and the Company’s strategy for the technology, the Company will be hosting a virtual investor event on January 8, 2025 at 9:30am ET.
This event be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241219061676/en/
Investors:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
Source: AngioDynamics, Inc.
FAQ
When will AngioDynamics (ANGO) report its Q2 FY2025 earnings?
What time is ANGO's Q2 FY2025 earnings conference call?
How can investors access ANGO's Q2 FY2025 earnings call?
What is the special investor event ANGO is hosting after Q2 earnings?
Until when will ANGO's Q2 FY2025 earnings call replay be available?
